The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders

Abstract

The World Health Organization Short Disability Assessment Schedule (WHO DAS-S) is an instrument for clinicians' assessment and rating of difficulties in maintaining personal care, in performing occupational tasks and in functioning in relation to the family and the broader social context due to mental disorders. The WHO DAS-S was developed and underwent preliminarily testing in the context of two international field trials of the multiaxial presentation of ICD-10 for use in adult psychiatry. The instrument was found to be useful, user-friendly and reasonably reliable for use by clinicians belonging to different schools of psychiatry and psychiatric traditions. Further work on the WHO DAS-S should include development of national adaptations of the instrument, studies of concurrent validity of the instrument and modification of the instrument to accommodate changes in the next edition of the International Classification of Impairments, Disabilities and Handicaps (ICIDH).

The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America’s First Trial of Heroin-Assisted Treatment

“…As eligible patients completed the screening, they provided informed consent and underwent the baseline assessment. Internationally established standardized assessment instruments were used including the European Addiction Severity Index (EuropASI), 38 SF-6D, 39 EQ5D, 40 WHO-DAS II, 41 and the Maudsley Addiction Profile. 42 Medical examinations and urinetoxicology were performed, and sociodemographic data and relevant institutional data on involvement with drug treatment, health care, and criminal justice were obtained.…”

Estimating Clinically Relevant Mental Disorders in a Rural and an Urban Setting in Postconflict Timor Leste

“…The measure has yielded sound psychometric properties in 2 multisite, international field trials. 41 …”

Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone

“…The following instruments, all validated and published for the Spanish population, were used to assess patients at enrollment: (1) EuropASI [14] , used to assess alcohol intake and its consequences, and the inclusion and exclusion criteria; (2) Alcohol Timeline Followback [15] , used to assess alcohol intake; (3) Obsessive Compulsive Drinking Scale (OCDS) [19] , used to assess alcohol craving; (4) Fagerström Test for Nicotine Dependence [20] , used to assess nicotine dependence; (5) International Personality Disorder Examination (IPDE) [21] , used to assess if the patient has a personality disorder; (6) Readiness to Change Questionnaire (RCQ) [22] , used to assess how ready and motivated the patient was to control his or her drinking; (7) WHO Psychiatric Disability Assessment Schedule (WHO/DAS) [23] , used to assess alcohol dependence-related disability; (8) European Quality of Life Questionnaire (EQ-5D) [24] , used to assess each patient's quality of life. The initial assessment also included blood tests to measure bio-logical markers of alcohol consumption [25] : ␥ -glutamyltransferase, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), mean corpuscular volume, and AST/ ALT ratio.…”